Wells Fargo
REGN icon

Wells Fargo’s Regeneron Pharmaceuticals REGN Stock Holding History

Wells Fargo’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$82.2K – 7673
2023
Q1 		$82.2K Buy
+100
New +$75.4K ﹤0.01% 4906
2022
Q1 		– Sell
-200
Closed -$126K – 7674
2021
Q4 		$126K Buy
+200
New +$123K ﹤0.01% 5512

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wells Fargo's REGN Position: Q1 2026 in Review

Wells Fargo increased its Regeneron Pharmaceuticals (REGN) stake by 1.4% in Q1 2026, buying an estimated $1.51M and bringing the position to 142,021 shares worth $110M. The position accounts for 0.02% of the portfolio, ranked #597.

Wells Fargo first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $580M in Q2 2015. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Wells Fargo held 142,021 shares of Regeneron Pharmaceuticals worth $110M as of Q1 2026.
  • Wells Fargo bought 1,972 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.51M.
  • Regeneron Pharmaceuticals made up 0.02% of Wells Fargo's portfolio in Q1 2026, its #597 holding.
  • Wells Fargo first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Regeneron Pharmaceuticals position peaked at $580M in Q2 2015.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.